Myelodysplastic Syndromes: all 2,165 studies
Page 14 of 22. Open to participants first (322), then studies with results posted, then the rest; newest registration first within each.
- A Study of Special Use Results Surveillance of Revlimid 5mg CapsulesCompletedNCT02921802
- Dose-escalation Study of Oral Administration of S 055746 in Patients With Acute Myeloid Leukaemia or Myelodysplastic SyndromeCompletedNCT02920541Phase 1
- Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATGCompletedNCT02916979Phase 1
- Eltrombopag for the Treatment of Thrombocytopenia Due to Low- and Intermediate Risk Myelodysplastic SyndromesActive, not recruitingNCT02912208Phase 2
- Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic SyndromeCompletedNCT02909972Phase 1
- Myelodysplasic Syndromes and Risk Factors for InfectionStatus unknownNCT02905552
- CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician ChoiceTerminatedNCT02900248
- An Observational Post Authorisation Study to Evaluate Safety and Efficacy in Patients Receiving Azacitidine in Daily Clinical Practice in the NetherlandsCompletedNCT02891551
- Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803CompletedNCT02890758Phase 1
- Epigenetics, Vitamin C and Abnormal Hematopoiesis - Pilot StudyCompletedNCT02877277Not applicable
- King's Invasive Aspergillosis Study IICompletedNCT02875743Phase 4
- Study Investigating the Interactions of Bone and Hematopoiesis in the ElderlyCompletedNCT02867085
- DNA Hypomethylating Agents and Lenalidomide in Elderly Patients With Myeloid Malignancies in the USWithdrawnNCT02863458
- Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell TransplantActive, not recruitingNCT02861417Phase 2
- Prophylactic DLI for the Prevention of Relapse Post HSCT in Patients With High Risk Myeloid MalignancyStatus unknownNCT02856464Phase 2
- Effect of Chemotherapy vs No Chemotherapy Pre-transplant to MDS Undergoing Allo-HSCTStatus unknownNCT02850822
- Single Agent and Combined Inhibition After Allogeneic Stem Cell TransplantTerminatedNCT02846376Phase 1
- A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (≥ 65 Years) With Haematologic NeoplasmsCompletedNCT02842229
- A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic SyndromesTerminatedNCT02841540Phase 1
- A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS)WithdrawnNCT02835794Phase 1/2
- Study of MRI Monitoring in Patients With Aplastic Anemia and Low or Int-1 Risk of MDS Complicated With Iron OverloadStatus unknownNCT02833493
- Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)WithdrawnNCT02829840Phase 1/2
- Plasmatic L-AScorbic Acid in MYelodyplastic Syndroms and ControlsCompletedNCT02809222Not applicable
- Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal InfectionsCompletedNCT02805946Phase 4
- Identification of Molecular Defects in Idiopathic Cytopenia of Undetermined SignificanceTerminatedNCT02804984
- Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous LeukemiaTerminatedNCT02795520Phase 1/2
- Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior TransplantationActive, not recruitingNCT02790515Phase 2
- Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCTWithdrawnNCT02786485Phase 1
- Combination Therapy of SyB C-1101 and Azacytidine in Patients With Myelodysplastic SyndromeWithdrawnNCT02783547Phase 1
- Evaluation of a Question Prompt List for Patients With Myelodysplastic Syndromes (QPL-MDS)Status unknownNCT02781441Not applicable
- A Clinical Trial Evaluating the Efficacy of Ultra Low Dose of Decitabine in Myelodysplastic Syndromes (MDS)Status unknownNCT02779569Not applicable
- The National Myelodysplastic Syndromes (MDS) StudyCompletedNCT02775383
- Prophylactic Application of Donor-derived TCM After Allogeneic HSCTCompletedNCT02758223Phase 1/2
- Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low RiskCompletedNCT02757989Not applicable
- CIK-Cells in Relapsing Patients With Acute Leukemia or Myelodysplastic Syndromes After SCT.Status unknownNCT02752243Phase 1/2
- Peptide Vaccination in Combination With Azacitidine for Patients With MDS and AMLCompletedNCT02750995Phase 1
- Azacitidine in Haploidentical Donor Hematopoietic Cell TransplantationTerminatedNCT02750254Phase 1
- Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic SyndromeTerminatedNCT02749708Phase 1
- G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCTCompletedNCT02744742Phase 2/3
- Phase 1/2 Study of CG200745 PPA for Myelodysplastic SyndromeActive, not recruitingNCT02737462Phase 1/2
- A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDSCompletedNCT02732184Phase 1
- Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCTTerminatedNCT02728700Phase 1
- Refining a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell TransplantationCompletedNCT02719821Not applicable
- Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP)Status unknownNCT02717884Phase 1/2
- PREDICTive FactOR of Overall Survival Among Geriatric Assessment Tools and Disease Related Factors in Elderly Patients With High Risk Myelodysplastic Syndromes.CompletedNCT02689622Not applicable
- A Study of PLX51107 in Advanced MalignanciesTerminatedNCT02683395Phase 1
- CAMELLIA: Anti-CD47 Antibody Therapy in Haematological MalignanciesCompletedNCT02678338Phase 1
- Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic SyndromeTerminatedNCT02676323Phase 1
- Allo HSCT Using RIC for Hematological DiseasesCompletedNCT02661035Phase 2
- Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer IndicationsCompletedNCT02649790Phase 1/2
- Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeCompletedNCT02649764Phase 1
- A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)TerminatedNCT02641002Phase 1
- Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCTTerminatedNCT02627573Phase 2
- Prospective Study of Molecular Predictors of Survival in Myelodysplastic SyndromesCompletedNCT02619565Not applicable
- Safety & Pharmacokinetics of Pegolsihematide for Treatment of Anemia Patient With Myelodysplastic SyndromesStatus unknownNCT02619097Phase 1
- Feasibility and Safety of Functional Performance Testing in Patients Undergoing Hematopoietic Cell TransplantationCompletedNCT02598752
- Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDSStatus unknownNCT02576301Phase 1/2
- Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic MalignanciesCompletedNCT02566395Phase 3
- Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)WithdrawnNCT02564536Phase 1
- Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMATerminatedNCT02562443Phase 3
- Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic SyndromeCompletedNCT02553941Phase 1
- A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML PatientsCompletedNCT02550535Phase 1/2
- Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic MalignanciesCompletedNCT02543879Phase 1
- MDS-CAN: A Prospective National MDS Clinical Database and Local Tissue BankStatus unknownNCT02537990
- Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic SyndromeActive, not recruitingNCT02530463Phase 2
- A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic SyndromesCompletedNCT02508870Phase 1
- A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced MalignanciesCompletedNCT02498665Phase 1
- Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM)CompletedNCT02494167Phase 1
- B7.1/IL-2 Leukaemia Cell Vaccine for Non-Transplant AML RFUSIN2-AML2 (NTX)Status unknownNCT02493829Phase 1
- Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 MutationCompletedNCT02492737Phase 1
- Evaluation of Cytidine Deaminase for Patient Suffering of a Myelodysplastic Syndrom or an AML Treated by AzacytidineStatus unknownNCT02489929Not applicable
- Allo-HSCT With Alternative Donor in Treatment of Hematologic MalignancyCompletedNCT02487069Not applicable
- Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After TransplantCompletedNCT02485535Phase 1
- Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic TransplantActive, not recruitingNCT02477878Phase 1
- Effect of Deferiprone on Oxidative-Stress and Iron-Overload in Low Risk Transfusion-Dependent MDS PatientsCompletedNCT02477631Phase 2
- Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCTCompletedNCT02472691Phase 2
- Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic SyndromeCompletedNCT02462252Phase 2
- Sertraline in Treatment of Low-Risk Myelodysplastic SyndromeTerminatedNCT02452983Phase 1
- Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)CompletedNCT02447666Phase 2
- Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute LeukemiaCompletedNCT02446964Phase 1
- PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML) (LAM-PIK)TerminatedNCT02438761Phase 2
- Study of DSP-7888 in Patients With Myelodysplastic SyndromeCompletedNCT02436252Phase 1/2
- iCare for Cancer PatientsTerminatedNCT02435550Not applicable
- Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome PatientsWithdrawnNCT02431351Phase 2
- Treatment of Anemia With Epoetin Beta in Low Risk Myelodysplastic Syndrome (MDS)CompletedNCT02428686Phase 2
- ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic SyndromeTerminatedNCT02392572Phase 1/2
- A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 MutationsActive, not recruitingNCT02381886Phase 1
- Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid LeukemiaTerminatedNCT02381548Phase 1
- Interventional Validation of an MDS-Specific Measure of Quality of Life: Assessing the Responsiveness of the Quality of Life in Myelodysplasia Scale (QUALMS-1) to Different Hypomethylating Agent Regimens for Low and Intermediate Risk DiseaseCompletedNCT02378701
- A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic SyndromeCompletedNCT02363491Phase 1/2
- Treosulfan-based Conditioning in Paediatric Patients With Haematological MalignanciesCompletedNCT02333058Phase 2
- Cohort Study of New Prognostic Factors With Peripheral Blood and Bone Marrow Evaluation at the Time of Diagnosis and Relapse in Myelodysplastic SyndromeStatus unknownNCT02330692
- A 5 Day Course of Fludarabine and Cytarabine Followed by Full Intensity Allogeneic Stem Cell Transplantation (FA5-Bucy) in Treating Patients With High-risk, Recurrent or Refractory Acute Leukemia and Advanced Myelodysplastic SyndromeStatus unknownNCT02328950
- A Study of LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome PatientsCompletedNCT02323139Phase 1
- Predictive Clinical and Biological Parameters in Acute Leukemia, Myelodysplastic Syndromes and Myeloproliferative Disorders-HEMATO-BIO-IPC-2013-015CompletedNCT02320656Not applicable
- Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell TransplantationCompletedNCT02312102Phase 1
- A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic SyndromeCompletedNCT02308761Phase 1
- Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCTCompletedNCT02294552Phase 2
- Blood Samples to Identify Biomarkers of BusulfanTerminatedNCT02291965
- Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int-1 MDS and Isolated Del(5q)CompletedNCT02279654